Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 3/20 | 0.39 |
| ▸ | ENO1 | P06733 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | CCR10 | P46092 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8895890 | 1.00 | KMT2A (0.57) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL8895125 | 1.00 | KMT2A (0.57) | KMT2ALMNATHRBCYP2C19CA12 | |
| Bromide SCHEMBL5137846 | 0.99 | KMT2A (0.56) | KMT2ALMNATHRBCYP2C19CA12 | |
| Bromide SCHEMBL8855507 | 0.99 | KMT2A (0.56) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL8855499 | 0.93 | KMT2A (0.55) | KMT2ALMNATHRBCYP2C19CA12 | |
| Bromide SCHEMBL8855612 | 0.92 | KMT2A (0.54) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL9085514 | 0.89 | KMT2A (0.58) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL8855564 | 0.88 | KMT2A (0.57) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL8855458 | 0.88 | KMT2A (0.57) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL8855559 | 0.88 | KMT2A (0.57) | KMT2ALMNATHRBCYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951213-B1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LTD (GB) | 2012-11-14 | — | — | EP | claimed |
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2010-04-29 | — | — | US | claimed |
| CN-101389320-A | Using alpha-hydroxycarbonyl compounds as reducing agents | MORVUS TECHNOLOGY LTD (GB) | 2009-03-18 | — | — | CN | claimed |
| US-5659048-A | CHEMOSENSITIZER, RADIOSENSITIZER ADMINISTERING TO PATIENTS WHOM ARE SENSITIVE TO RADIATION OR CHEMOTHERAPY | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-08-19 | — | — | US | claimed |
| US-5652255-A | ADMINISTERING NITROIMIDAZOLE DERIVATIVE NITRIC OXIDE SYNTHASE INHIBITOR; ANTITUMOR AGENTS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-07-29 | — | — | US | claimed |
| EP-0319329-B1 | Nitro-substituted aromatic or hetero-aromatic compounds for use in cancer treatment | BRITISH TECH GROUP (GB) | 1995-11-02 | — | — | EP | claimed |
| WO-1994015922-A1 | NOVEL PROCESS FOR PREPARING CHIRAL [[(2-BROMOETHYL)AMINO]METHYL]-2-NITRO-1H-IMIDAZOL-1-ETHANOL AND RELATED COMPOUNDS | WARNER LAMBERT COMPANY (US) | 1994-07-21 | — | — | WO | claimed |
| US-5073639-A | Reacting a 2-oxazolidinone and a 2-nitroimidazole in the presence of potassium or cesium carbonate and treating the resulting compound with a hydrophalic acid | WARNER-LAMBERT COMPANY (US) | 1991-12-17 | — | — | US | claimed |
| EP-0375951-A1 | A new process for the synthesis of novel and known nitroimidazoles which are useful as sensitizing agents | WARNER-LAMBERT COMPANY (US) | 1990-07-04 | — | — | EP | claimed |
| US-10398676-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-10357577-B2 | Bacterial nitroreductase enzymes and methods relating thereto | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-07-23 | — | — | US | disclosed |
| CN-103315995-B | Use alpha-hydroxy carbonyl compounds as reducing agent | 莫沃斯技术有限公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20180140575-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2018-05-24 | — | — | US | disclosed |
| US-9907784-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | MORVUS TECHNOLOGY LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-5073639-A | Reacting a 2-oxazolidinone and a 2-nitroimidazole in the presence of potassium or cesium carbonate and treating the resulting compound with a hydrophalic acid | WARNER-LAMBERT COMPANY (US) | 1991-12-17 | — | — | US | disclosed |
| US-5036096-A | Sensitizers used in radiation and chemotherapy treatment of tumors | WARNER-LAMBERT COMPANY (US) | 1991-07-30 | — | — | US | disclosed |
| US-5036089-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1991-07-30 | — | — | US | disclosed |
| US-4954515-A | RADIOSENSITIZING OR CHEMOSENSITIZING AGENTS IN THE TREATMENT OF HYPOXIC TUMOR CELLS | WARNER-LAMBERT COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0375951-A1 | A new process for the synthesis of novel and known nitroimidazoles which are useful as sensitizing agents | WARNER-LAMBERT COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0319329-A2 | Nitro-substituted aromatic or hetero-aromatic compounds for use in cancer treatment | BTG INTERNATIONAL LIMITED (GB) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | KMT2A 3827/4885LMNA 763/4885THRB 3904/4885 |
| US-10398676-B2 | Use of alpha-hydroxy carbonyl compounds as reducing agents | DERA, HOGA1, ALDOA | KMT2A 3827/4885LMNA 763/4885THRB 3904/4885 |
| US-20180140575-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | KMT2A 3827/4885LMNA 763/4885THRB 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.